Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rofecoxib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Acetaminophen | EXPERIMENTAL | Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP |
| Refecoxib 12.5 mg | ACTIVE_COMPARATOR | Rofecoxib: Capsules 12.5 mg, oral, C-904-1A |
| Rofecoxib 12.5 x 2 | ACTIVE_COMPARATOR | Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A |
| Name | Type | Description |
|---|---|---|
| acetaminophen | DRUG | Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication. |
| Rofecoxib | DRUG | Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication. |
Inclusion Criteria: * Symptomatic idiopathic osteoarthritis of the knee for a minimum of six months duration requiring treatment with either an analgesic or anti-inflammatory agent on a regular basis (greater than or equal to three days/week) for at least three months. * A history of osteoarthritis...
Rofecoxib is an investigational small molecule being studied for the treatment of osteoarthritis of the knee. It is a nonsteroidal anti-inflammatory drug under development by Johnson & Johnson. The drug is intended for patients with this condition, and it has been evaluated in a Phase 3 clinical trial.
Rofecoxib is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is a small molecule intended for the treatment of osteoarthritis of the knee. It has been studied in a Phase 3 clinical trial.
Rofecoxib is in Phase 3 clinical development. It has completed one Phase 3 trial for osteoarthritis of the knee, and no active trials are currently listed. The drug is investigational and has not been approved by regulatory authorities.
Rofecoxib has been studied in one completed Phase 3 clinical trial, identified as NCT00568295. This trial was a four-week study comparing acetaminophen extended release and rofecoxib in the treatment of osteoarthritis of the knee. The trial enrolled 403 participants and was randomized, double-blind, and active-controlled.
No, Rofecoxib is not the same as acetaminophen. Rofecoxib is an investigational drug being developed by Johnson & Johnson for osteoarthritis of the knee. In a clinical trial, it was compared against acetaminophen extended release as an active control, but the two are distinct medications.